Noninvasive cytology-based assay could provide screening at a reasonable cost.

Biomoda and New Mexico Institute of Mining and Technology are partnering to develop a diagnostic product for lung cancer. The collaborators will work together on clinical studies to develop a specialized image-recognition technology.


This is a part of the company’s commercialization of its assay for the early detection of lung cancer. Biomoda’s technology, a noninvasive cytology-based assay, is designed for cancer screening of large populations at a reasonable cost.


Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive, according to the company.

Previous articleBioWa and Lonza Will Pool Tools to Develop Enhanced Antibody Platform
Next articleMuscular Dystrophy Association Funding Will Aid Insmed’s Late-Stage Trial